The U.S. National Institute of Allergy and Infectious Diseases says enrollment into an international HIV/AIDS trial has been halted.
The trial was to compare continuous antiretroviral therapy with episodic drug treatment guided by levels of CD4+ cells. But enrollment was stopped because patients receiving episodic therapy had twice the risk of disease progression into clinical AIDS or death.
NIAID made the decision to halt enrollment following a recommendation from an independent Data and Safety Monitoring Board that was charged with regularly evaluating data and safety issues during the multi-year trial.
The trial, known as Strategies for Management of Anti-Retroviral Therapy, or SMART, was designed to determine which of the two different HIV treatment strategies would result in greater overall clinical benefit.
The trial involved an international collaboration of 318 clinical sites in 33 nations. It began enrollment in January 2002 and had successfully recruited more than 90 percent of its target of 6,000 participants when enrollment was stopped.
The investigators say they will analyze the SMART study data to gain insights into the reasons for the increased risk.
Copyright 2006 by United Press International
Related stories:
New study of targeted therapies for breast cancer -- model for global clinical trials
Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research.
Stroke risk factors may signal faster cognitive decline in elderly
Older Americans with the highest risk of stroke, but those who have never suffered a stroke, also have the highest rate of cognitive decline, researchers reported at the American Stroke Association’s International Stroke Conference 2008.
Doctors aggressively treat early heart attacks, research shows
An international study involving 467 hospitals in 12 countries found that doctors do a good job of aggressively treating the early stages of heart attacks – even before laboratory tests confirm the diagnosis.
AIDS vaccine trial exceeds expectations
An experimental AIDS vaccine of Merck & Co. has exceeded expectations and led to a double enrollment in the trial to 3,000, researchers said.
Immune system protein accurate predictor of survival in pediatric septic shock
About 4,000 children in the United States die every year from uncontrolled infections of the body known as septic shock, and researchers are pushing the boundaries of molecular science to find new therapies that can stem the condition. But a simple measure of an immune system protein within 24 hours of being admitted to the hospital for septic shock can predict survival in children, yielding a powerful tool for diagnostics and clinical trials of new septic shock therapies, according to a research team led by Cincinnati Children's Hospital Medical Center in the Aug. 1
American Journal of Respiratory and Critical Care Medicine.
Gene panel predicts lung cancer survival, study finds
Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment. The study, the largest of its kind, appears online in
Nature Medicine.
Most ongoing diabetes trials do not include outcomes important to patients
An analysis of ongoing randomized clinical trials (RCTs) in diabetes finds that only about 20 percent have as primary outcomes results that patients consider important, such as illness, pain, effect on function and death, according to a study in the June 4 issue of JAMA.
New vaccine approach prevents/reverses diabetes in lab study
Results of study are published in Diabetes, a journal of the American Diabetes Association
Microspheres carrying targeted nucleic acid molecules fabricated in the laboratory have been shown to prevent and even reverse new-onset cases of type 1 diabetes in animal models. The results of these studies were reported by diabetes researchers at the John G. Rangos Sr. Research Center at Children’s Hospital of Pittsburgh of UPMC and Baxter Healthcare Corporation.